Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Tracking The Priority Review Vouchers

Executive Summary

A chart showing the status of the 10 FDA priority review vouchers awarded to date for tropical disease and rare pediatric disease treatments.

Advertisement

Related Content

Gilead, With Two PRVs In Hand, Holds Options For Accelerating Late-Stage Pipeline
Sponsors May Race For Rare Pediatric Voucher Designations As Deadline Nears
Voucher Does Not Guarantee A Priority Review, FDA Says
Priority Review Voucher Program For Rare Pediatric Diseases Extended As FDA Lowers Fee
Pediatric Rare Disease Voucher Program Faces Expiration
Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems

Topics

Advertisement
UsernamePublicRestriction

Register

PS118850

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel